The offering provides a modest cash runway extension but does not resolve the going-concern risk. Watch for the NDA submission in early Q4 2026 and any FDA feedback; failure to secure additional financing or a positive regulatory catalyst could accelerate the cash burn timeline.
Price Chart
Executive Summary
Clene Inc. is raising approximately $4.0 million in gross proceeds through a direct offering of 1,219,513 shares at $3.28 per share, with $2.1 million of that total coming from directors and officers. The company has a going-concern warning, only $9.7 million in cash as of June 30, 2026, and is burning through cash to fund its NDA submission for CNM-Au8 in ALS. The offering provides near-term liquidity but adds ~9.4% dilution to existing shareholders, and the stock is trading at the offering price.
Key Facts
- Offering of 1,219,513 shares at $3.28 per share for ~$4.0 million in gross proceeds
- Directors and officers purchasing ~$2.1 million of the offering
- Pro forma shares outstanding will increase to 14,213,981 from 12,994,468
- Cash and cash equivalents were $9.7 million as of June 30, 2026
- Accumulated deficit of $329.8 million as of June 30, 2026
- Going concern warning: expects insufficient cash within 12 months without additional financing
- Loss from operations of $5.3 million for Q2 2026 and $7.4 million for H1 2026
- Net cash used in operating activities was $7.1 million for H1 2026
- Immediate dilution of $4.77 per share for new investors
- NDA submission for CNM-Au8 planned for early Q4 2026
Financial Impact
~$4.0 million gross proceeds, ~9.4% dilution to existing shareholders, immediate $4.77 per share dilution for new investors
Risk Factors
- Going concern risk: company may not have sufficient cash within 12 months
- Substantial dilution: 9.4% increase in shares outstanding, with massive overhang from 7.9M warrants and 1.6M convertible shares
- No approved products and no drug revenue; clinical-stage only
- NDA submission for CNM-Au8 is not guaranteed to be accepted or approved
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001437749-26-030521 |
| Document: 0001437749-26-030521-index-headers.html | 0001437749-26-030521 |
| Document: 0001437749-26-030521-index.html | 0001437749-26-030521 |
| Document: 0001437749-26-030521.txt | 0001437749-26-030521 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $3.73 | awaiting T+20 | — | $3.84 (+2.95%) |
Oct 19, 2026 8d ago | 8-K | $3.29 | awaiting T+20 | — | $3.84 (+16.72%) |
Oct 19, 2026 8d ago | Press Release | $3.29 | awaiting T+20 | — | $3.84 (+16.72%) |
Oct 13, 2026 13d ago | SC 13G/A | $3.39 | awaiting T+20 | — | $3.84 (+13.27%) |
Sep 16, 2026 5w ago | 8-K | $4.15 $3.31 | ▲ +20.36% | ▲ +21.57% | $3.84 (+7.47%) |
Sep 16, 2026 5w ago | 424B5 | $3.86 $3.31 | ▲ +14.25% | ▲ +16.31% | $3.84 (+0.52%) |
Aug 14, 2026 10w ago | 8-K | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.84 (−7.25%) |
Aug 14, 2026 10w ago | Press Release | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.84 (−7.25%) |
Aug 10, 2026 11w ago | 8-K | $5.16 $3.62 | ▼ −29.84% | ▼ −28.93% | $3.84 (−25.58%) |
May 14, 2026 23w ago | 8-K | $7.05 $5.84 | ▼ −17.16% | ▼ −16.30% | $3.84 (−45.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers